BioSpace News Archive

FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block FX301 may provide 3 to 5 days of non-opioid pain relief while preserving motor function following musculoskeletal surgery

OrbiMed, a leading life sciences investment firm, announced $3.5 billion in commitments for its latest private investment funds, including $1.5 billion for OrbiMed Private Investments VIII, $800 million for OrbiMed Asia Partners IV, and $1.2 billion for OrbiMed Royalty & Credit Opportunities III. Investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds

Nuvo Pharmaceuticals Inc. has entered into an exclusive license and supply agreement (the License Agreement) with The Mentholatum Company for the exclusive right to commercialize the Resultz formula and technology in the United States under the Mentholatum® brand.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with hypertriglyceridemia.

Biohaven reports NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael Rice to its board of directors.

Stericycle, Inc. (NASDAQ: SRCL), a leading provider of medical waste and secure information destruction solutions, today announced that Chief Executive Officer Cindy Miller has joined more than 1,600 CEOs pledging to take action to advance diversity and inclusion in the workplace through the CEO Action for Diversity & InclusionTM coalition

CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 million and CARISMA’s total capital raised to date to nearly $121 million.

The global plasma protease C1-inhibitor treatment market is foreseen to display robust growth in the future due to the increasing cases of acute hereditary angioedema and prophylaxis.

The global porcine vaccines market is expanding due to growing prevalence of swine diseases across the globe.